BRIEF — Omeros Corporation To Terminate Yartemlea Compassionate — Use Program In Europe Due To US Demand

Oct 16 (Reuters) — Omeros Corporation: Omeros Corporation Receives Chmp Negative Opinion Following Re-examination Of European Marketing Authorization Application For Narsoplimab In Ta-tma Omeros Corporation - To Terminate Yartemlea Compassionate-use Program In Europe Due To U.s. Demand Omeros Corporation - Plans Clinical Studies In Ards And High-risk Ta-tma In Pediatric Patients Later This Year Source text:... Further company coverage: OMER.O (Reuters.Briefs@thomsonreuters.com;)